KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Phase 3 study results for oral PCSK9 inhibition with enlicitide.

Irina Müller-Kozarez, Ulrich Laufs

Med 7(4) 101097

PMID41966715
PMCID-
DOI10.1016/j.medj.2026.101097
发表日期2026-04-12
摘要

摘要

Two large randomized, placebo-controlled phase 3 trials, CORALreef Lipids1 and CORALreef heFH,2 demonstrated that once-daily oral enlicitide lowered LDL cholesterol by approximately 56%-60% on top of background lipid-lowering therapy. Reductions were sustained through 24-52 weeks and accompanied by improvements in other lipid parameters. Safety outcomes were comparable to placebo, with efficacy similar to monoclonal antibody PCSK9 inhibitors.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。